Ocera to Present at the Cowen and Company 36th Annual Health Care Conference

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2016 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the Cowen and Company 36^th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, Massachusetts from March 7-9, 2016. Ocera’s presentation will take place in Salon H on Monday, March 7^th at 3:20 PM Eastern Time. 

A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 90 days following the conference for those unable to listen live.

About Ocera

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.

OCRX-G

Contact:
Susan Sharpe
Ocera Therapeutics, Inc.
[email protected]
919-328-1109